Tt Electronics Share Discussion Threads

[earwacks] 23/4/2021 09:57

Actually they did not raise money for Virlolens. They got a 5 million government grant to develop it. They did a raise money to buy an American electrical earnings enhancing company. You are wrong about the validity of the accreditation. Keyoptions are in the final stages now. They have signed another partner to distribution deal. You sound just like that idiot journalist from the FT. Do your research properly and stop inventing inaccurate and misinformation. Many thanks

[glavey] 23/4/2021 01:25

MRHA Registration does not verify product efficacy or represent any form of accreditation, certification or approval.
"Virolens" or "iAbra" are not currently indicated.
The 'test centres' seem to be testing the product idea, not the participants.
The video doesn't not show a functioning covid test centre. It is just a shows a film set.
Read carefully, the information on the websites is telling.
It seems one can book a test for all days at any time of day. It seems one has to pay £50 to find out if a booking will be confirmed.
Does anyone know of any person who has participated and, if so, their experience?
TT have already used this covid related PR to ramp the share price to get a raise away.

[aringadingding] 22/4/2021 15:45

Do you mean 'we might get some news soon' or 'there is scheduled to be some news soon'?

[tinnerz187] 22/4/2021 15:24

Nice volume today! News pending

[aringadingding] 06/4/2021 15:09

Good spot. Yeah when I heard about mass roll out of weekly testing I got excited but seems to be mostly lateral flow that I have read about for this. But possible that virolens in the UK will be used for international travel. Not sure about workplaces? It would be nice to know, if getting on a plane, that everyone had had a test before getting on the plane (and good for the UK to know that for incoming planes also). Boss of Heathrow was an early advocate i'm sure you'll remember. Boris' announcement yesterday was "watch this space" for intl travel.

Beyond that I guess with slow roll vaccinations overseas there is short term hope for overseas sales.

The long term applications of holographic technology are extremely interesting, but longer term.

[sphere25] 06/4/2021 14:53

Big chunks going through at 230p:

2.6m
1m
800k
861k

16:37 UPDATE:

Price has held up well on those sells so clearly buyers happy to pick up slugs there.

Map it out. Looks like 230p vs 233p.

Will keep a watch tomorrow.

All imo
DYOR

[wjccghcc] 27/3/2021 13:02

Regarding MRHA registration, it’s the same requirement as for any of the Lateral Flow Tests that are being used (Excalibur, Innova etc.). They all quote the sensitivity / specificity figures from 400 clinical samples (150 positive / 250 negative) with different viral loads as required by the MHRA.

We saw with Innova that the LFT results in real life situations are a lot worse than their registration details.

iAbra were running a live trial in February in The City looking for 400 people and then checking them with PCR tests. I’d be surprised if they went ahead with registration if that hadn’t given at least acceptable results, particularly after the media backlash in September.

I see there is an instant test centre already set up in the City where they did the trial and watching the video shows it to be a much quicker/simpler/less painful process than LFT/PCR tests.



They're charging £50 for an individual test but I suspect a corporate bulk buyer could get them for less than half that.

The news has added £45mm to the TTG market cap which is negligible compared to the LFT/PCR providers (AVCT have >450mm, ODX>125mm rises since their LFT news). If it doesn't take off, the downside is 25p but if they do get 100mm orders a year, the upside is at least 4 times that - a good tradeoff IMHO.

[aringadingding] 27/3/2021 12:30

In the article posted by Glavey, I think that media communications training firm is absolutely right to highlight the risks involved in putting out press releases and thus the value of their training.

However, if we step back and think about it, does an exaggeration in a press release warrant a savaging of an innovative start up business?

The exaggeration I am referring to is the claim that Bristol University had been involved in the trial design. I can't see any other exaggerations, really, and indeed I note the quoted 96.7% specificity (in September 2020) is now discussed as 99.7% (in March 2021).

This is real life, this is business, and people make mistakes, including in press releases, but people should also be allowed to move on from them.

There were three separate FT articles at the time. They were often dismissive and personal in their attacks made on an innovative company that should be at the very least respected as a matter of course. Rather than engaging brain and doing research, people in a comfy job in London wrote articles disparaging the work of entrepreneurs because they were based "40 miles north of London", equating all physical technology companies with each other and comparing the situation to Theranos. Have they not heard of Cambridge, which is around 60 miles north of London?

In the spirit of forgiveness and moving on I think the FT journalists should also be allowed to learn the lessons and move on. Indeed I should probably move on as well and look forward to the opportunities to deploy the technology. I'm just pointing out that there are multiple parts to the case study.

[earwacks] 27/3/2021 09:55

Hi Glavey. The last placing was to purchase earnings enhancing US electronics and design manufacturer Torotel, nothing to do with virolens. Schroder bought 5% of TTG last week having sold back in September.
I think the results of the recent tests of Virolens would absolutely be price sensitive information as will forthcoming orders when received. What they absolutely do not want is misrepresentation by the media again, so they have sensibly been more cautious on fuelling the sensationalist interpretations of the press.
Naturally a lot depends on the sales of these machines which have brought a great deal of media attention and interest declared by many sectors of commerce eager to to open up business in a safer environment.

[glavey] 27/3/2021 06:19

"They have been at pains to stress that there is no guarantee of any financial impact from Virolens."

Didn't need an RNS then.

[aringadingding] 26/3/2021 12:03

PS - for example from the link, when you cough up sputum it can take upper respiratory tract endothelial cells with it, thus confusing the interpretation of the sample, because it might show the presence of upper RT viruses while in fact the lower RT is infected with bacteria. So you need to see how many endothelial cells are in there. But maybe the machine could do all those things at the same time, thus saving the time and effort required for multiple cultivations to take place and providing actionable information at a justifiable cost.

[aringadingding] 26/3/2021 11:57

Hi aarwacks and wjccghcc, thanks very much for both of those comments. Great to see that trial data and I would assume the due diligence of MHRA on that data has been thorough. The press mentioning both sensitivity and specificity, whatever next!

Yeah don't get me wrong, if they can sell loads of machines in the coming months then I am not going to complain... but lets say the stock goes to 600p, should one then sell or stay in because they are only just getting started in this area?

I take your point the short term buyers are private sector but it is entirely possible other viruses come along. I wouldn't think it takes that long to train the computer to recognise a new pathogen and then roll it out worldwide, but manufacturing the machines certainly will take time. Thus machines could be bought in advance.

In fact I have just realised that hospitals could use the machines in sputum assessment / pathogen identification. Now that is a big market, and so big that new entrants are unavoidable. But first mover advantage, and the value of selling the hardware not the software, should not be underestimated. For example in chest infections, distinction even between bacteria and viruses is complex at present. Hence this quote comes from the link below:

"New approaches for respiratory pathogen detection are desperately needed."

hxxps://academic.oup.com/cid/article/54/suppl_2/S146/376724

[wjccghcc] 26/3/2021 10:48

98.1% sensitivity and 99.7% sensitivity is as good as the best LFTs and the cartridges are recyclable.

[earwacks] 26/3/2021 10:46

Aringading. Some interesting points. Firstly Histate, which is distributing the test, said it would launch with immediate effect following the approval in the UK by
the Medicines and Healthcare products Regulatory Agency (MHRA),
and was hoping for a further rollout in coming months.

Histate said trials had indicated the test had 98.1%
sensitivity, meaning it returns few false negatives, and 99.7%
specificity, meaning few false positives.
So I don't think they are any less accurate than the best out there. Secondly its not up to the government to buy them ( they put up 5 million to develop this), possibly local councils could be interested. In the main their customers would be sports and entertainment events, travel, workplace and hospitality. They reckon each machine can do 'hundreds of tests a day so a sports event would probably need about 100 machines. TG have facilities to manufacture these here and in the states and probably other countries too. If the orders become substantial which is quite conceivable TTG will need to scale up production which I would hope they are well prepare for.
As regards buying for future pandemics that relies on efforts to redesign virolens to detect other virus and bacterial infections. Work currently in progress

[aringadingding] 26/3/2021 10:16

Hi all I'm new to this thread though have held TT for a couple of years. Any views on the below?

Key applications of virolens:

- Ending this pandemic
- Controlling flu viruses
- Insurance policy against next pandemic.

Discussion on the last bullet only:

I think a key question is whether governments can be persuaded to stock up on machines in advance of the next pandemic. I think there is a very strong case that they should. I think they are intended to work in parallel with lateral flow tests. They are much lower cost per test done, and much faster, but I think maybe less accurate (though I’m not sure about that, but let's assume so for now).

So I think the idea is that if we had had these machines, and a lateral flow test (which doesn’t take long to develop) at the start of the pandemic, then every school, workplace and sporting event could basically stay open. People would queue up at the start of the day and be tested. If the machine says they might have the disease then they take the lateral flow test (which only takes say 20 minutes anyway). If that says they have the disease they go home, if not they go to school/work.

So it’s not a complete guarantee system, but I think there is a very strong case that, if we had had that at the start of this pandemic, then while shops and pubs would have had to close, many schools and workplaces would have been able to stay open, and the R number would have gone very low as a result of the management via these machines. Shops and pubs would have to stay closed until a vaccine was developed (which will be faster next time also probably – or should be anyway). So for the period of time when the vaccine is being developed the impact of the pandemic is much much lower because of these machines – it’s like an insurance policy.

If selling at £10k (<-?) then £50m revenue would be 5,000 machines. Doesn't seem like a lot.

[sphere25] 26/3/2021 08:43

Price currently 237p and keeps knocking its head against 240p - clearly sellers in size there at the moment. The first time this news was brought out, the market scrambled all over it with volume approaching 8 million. There was a placing shortly after which did raise a few eyebrows!

Clearly the interest isn't there this morning with only 517k shares exchanging hands so far. One to keep an eye on to see if any bigger buyers come in and back what looks like rather uncertain upside potential with Virolens(R).

All imo
DYOR

[mammyoko] 26/3/2021 07:33

They have been at pains to stress that there is no guarantee of any financial impact from Virolens. Not your usual ramptastic type of RNS.

[glavey] 26/3/2021 05:01

What are they up to now, another placing?

It's only six months since the last time they 'tried it on', have people such short memories?

[zxie] 25/3/2021 20:13

It is highly recommended (KOD) next GGP

[lawdoc] 25/3/2021 13:16

An article in today's Shares magazine under this weeks "Great Ideas". The rise in share price may have been prompted by the article and reinforced with today's Virolens status RNS.

[ga02njd] 25/3/2021 13:03

is there any particular news out today?

[peddlers] 25/3/2021 11:48

nice rise today ,